DA Davidson Has Lowered Expectations for USANA Health Sciences (NYSE:USNA) Stock Price

USANA Health Sciences (NYSE:USNA) had its price objective cut by analysts at DA Davidson from $38.00 to $36.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. DA Davidson’s price objective would suggest a potential upside of 25.92% from the company’s current price. DA Davidson also issued estimates for USANA Health Sciences’ Q1 2025 earnings at $0.83 EPS, FY2025 earnings at $2.57 EPS and FY2026 earnings at $2.68 EPS.

Other equities research analysts have also recently issued research reports about the stock. Sidoti cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th.

USANA Health Sciences Trading Down 13.9 %

Shares of USNA stock traded down $4.62 on Thursday, hitting $28.59. 246,846 shares of the stock were exchanged, compared to its average volume of 154,153. The firm’s 50 day moving average is $33.62 and its two-hundred day moving average is $36.61. USANA Health Sciences has a one year low of $27.71 and a one year high of $50.32. The firm has a market capitalization of $544.93 million, a PE ratio of 10.11, a P/E/G ratio of 0.93 and a beta of 0.87.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The firm had revenue of $213.61 million during the quarter, compared to analyst estimates of $208.82 million. On average, sell-side analysts expect that USANA Health Sciences will post 2.45 earnings per share for the current year.

Institutional Trading of USANA Health Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. R Squared Ltd purchased a new position in shares of USANA Health Sciences during the 4th quarter valued at $28,000. Safe Harbor Fiduciary LLC bought a new stake in USANA Health Sciences during the third quarter valued at $30,000. KBC Group NV grew its position in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after buying an additional 519 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in USANA Health Sciences in the 4th quarter worth about $83,000. Finally, Quantbot Technologies LP bought a new position in USANA Health Sciences in the 4th quarter worth about $132,000. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.